Week In Review: Three Months After Privatizing, WuXi PharmaTech Plans IPO For Biologics Unit

Published: Feb 29, 2016

WuXi PharmaTech, China's largest CRO/CMO, is planning to conduct a Hong Kong IPO of its biologics subsidiary that values the unit at $1.5 billion; Impact Therapeutics, a Nanjing innovative drug developer, completed a $10 million Series B funding from China venture capitalists; Canada's Aurinia Pharma reported Luveniq (voclosporin), a potential treatment for lupus nephritis, produced positive data in early results from a Phase IIb trial, currently underway in Malaysia; Bristol-Myers Squibb released results from a successful Phase III trial of its all-oral hepatitis C combination treatment in a predominantly Chinese patient population; the CFDA suspended its anti-counterfeiting electronic drug monitoring system, which was administered by Alibaba Health Information Technology; and JHL Biotech, a Taiwan-China biotech, completed mechanical construction of its Wuhan biotech manufacturing facility, a prefabricated building made by GE Healthcare.

Back to news